Azzalure botulic toxin wins EU approval
French independent pharma group Ipsen has received collective marketing approval from 15 EU member states to market its botulic toxin Azzalure to treat facial wrinkling.
French independent pharma group Ipsen has received collective marketing approval from 15 EU member states to market its botulic toxin Azzalure to treat facial wrinkling.
Ipsen sold development and distribution rights in the EU for the aesthetic indications of its botulic toxin in 2007 to the Nestle-L'Oréal joint venture Galderma. The toxin was originally developed by Allergan of the US as Botox as a treatment for muscular spasm. Ipsen has said it hopes to receive US marketing approval in mid-2009.